EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

CD44v6- and VEGFR2-targeting antibody-drug conjugates: Enhancing precision and safety in cancer therapy through a dual-targeting strategy

Menghuai Wu, Xuezhe Feng, Wenqiang Huang, Ye Wu, Juanjuan Cui

Protein & Peptide Letters · 2026

DOI: 10.1016/j.ppl.2026.07.001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Protein & Peptide Letters, 2026. Verfasst von Menghuai Wu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Stomatology, The First Affiliated Hospital of Anhui Medical University, China. Hauptthemen laut MEDLINE: Vascular Endothelial Growth Factor Receptor-2, Hyaluronan Receptors, Immunoconjugates, Antibodies, Bispecific. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Anhui Medical University, Anhui Provincial Key Research and Development Plan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Bispecific antibody-drug conjugates (BsADCs) represent a promising therapeutic strategy to overcome single-target resistance. Here, we developed a dual-targeting BsADC that simultaneously recognizes CD44v6 and VEGFR2. METHODS: Spatial configurations were optimized in CHO expression systems. In vitro binding affinities and cytotoxicity were evaluated alongside in vivo anti-tumor efficacy and systemic toxicity in xenograft models. RESULTS: The variant BIWA8-(G4S)2-DC101-scFv exhibited high stability and an SEC purity of 84.6%. The construct retained antigen-binding affinity and mediated dose-dependent cytotoxicity in vitro. In mouse xenograft models, the dual-targeting BsADC showed potential anti-tumor activity compared to single-target controls, with no overt body weight loss or observable physical toxicity detected during treatment. CONCLUSION: These findings suggest that the CD44v6/VEGFR2-targeting BsADC represents a potential candidate for targeted cancer therapy. LIMITATIONS: High-resolution LC-MS characterization for absolute DAR distribution and long-term toxicity evaluations in non-human primates were not performed in this preliminary work.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vascular Endothelial Growth Factor Receptor-2Hyaluronan ReceptorsImmunoconjugatesAntibodies, BispecificAntineoplastic AgentsNeoplasmsAnimalsHumansMiceCricetulusXenograft Model Antitumor AssaysCHO CellsCell Line, Tumor

Stichwörter der Autor:innen

Bispecific antibody-drug conjugatesCD44v6Cancer therapyDual-targeting strategyVEGFR2

Substanzen

Vascular Endothelial Growth Factor Receptor-2Hyaluronan ReceptorsImmunoconjugatesAntibodies, BispecificCD44v6 antigenKDR protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Stomatology, The First Affiliated Hospital of Anhui Medical University, China.
  • Department of Human Resources, The First Affiliated Hospital of Anhui Medical University, China.
  • Department of Stomatology, The First Affiliated Hospital of Anhui Medical University, China. Electronic address: cuijuanjuan@ahmu.edu.cn.

Förderung

  • Anhui Medical University
  • Anhui Provincial Key Research and Development Plan

Zitieren

APA

Wu, M., Feng, X., Huang, W., Wu, Y., & Cui, J. (2026). CD44v6- and VEGFR2-targeting antibody-drug conjugates: Enhancing precision and safety in cancer therapy through a dual-targeting strategy. Protein & Peptide Letters. https://doi.org/10.1016/j.ppl.2026.07.001

Vancouver

Wu M, Feng X, Huang W, Wu Y, Cui J. CD44v6- and VEGFR2-targeting antibody-drug conjugates: Enhancing precision and safety in cancer therapy through a dual-targeting strategy. Protein & Peptide Letters. 2026. doi:10.1016/j.ppl.2026.07.001

BibTeX
@article{Wu2026,
  author = {Wu, Menghuai and Feng, Xuezhe and Huang, Wenqiang and Wu, Ye and Cui, Juanjuan},
  title = {CD44v6- and VEGFR2-targeting antibody-drug conjugates: Enhancing precision and safety in cancer therapy through a dual-targeting strategy},
  journal = {Protein & Peptide Letters},
  year = {2026},
  doi = {10.1016/j.ppl.2026.07.001}
}
Kostenlos starten →